What is the chemical difference between GHK-Cu and free GHK, and why does it matter for research?

GHK (Gly-His-Lys) is a naturally occurring tripeptide that binds cupric copper (Cu²⁺) with exceptionally high affinity (association constant approximately 10¹⁵ M⁻¹), forming the GHK-Cu complex. The histidine imidazole nitrogen, the α-amino group of glycine, and the deprotonated amide nitrogen contribute to the square-planar coordination geometry around copper. This coordination does not simply add copper to an inert scaffold — it creates a chemically distinct molecular entity with altered conformation, charge distribution, and protein interaction profile. In most wound-healing and collagen synthesis research, GHK-Cu is the biologically active species, not free GHK alone. Free GHK is thought to function as an endogenous copper transporter, sequestering and delivering Cu²⁺ to sites of tissue remodeling where copper-dependent enzymes such as lysyl oxidase and cytochrome c oxidase operate. Researchers sourcing these compounds for laboratory use should specify which species they are working with. Commercially supplied "GHK-Cu" should be characterized by mass spectrometry to confirm copper loading, as the copper-to-peptide ratio directly affects observed potency in cell assays.

How does copper coordination alter GHK activity in preclinical wound and collagen models?

GHK without copper shows limited activity in standard in vitro collagen synthesis assays. GHK-Cu, by contrast, activates TGF-β1 synthesis and downstream Smad2/3 signaling in fibroblast cultures, upregulating type I and type III collagen expression. Copper appears necessary for GHK-Cu's interaction with the decorin–TGF-β regulatory axis, which controls collagen fiber assembly. Additionally, Cu²⁺ within the complex is co-delivered to lysyl oxidase — a copper-dependent cross-linking enzyme — supporting collagen and elastin stabilization in extracellular matrix research models. Wound contraction scratch assays show GHK-Cu induces greater fibroblast migration than equimolar free GHK under otherwise identical laboratory conditions. Anti-inflammatory effects — notably TNF-α and IL-6 suppression in LPS-stimulated macrophage cultures — are also consistently more pronounced with the copper complex than with free GHK. Hair follicle research models using GHK-Cu have noted upregulation of keratinocyte growth factor (KGF/FGF-7), a finding not reliably replicated with free GHK preparations, suggesting that the copper coordination is mechanistically essential rather than incidental.

What explains the age-related decline in plasma GHK, and how is this studied in longevity research?

Plasma concentrations of free GHK decline markedly with age. Pickart's foundational analyses and subsequent plasma studies reported concentrations of approximately 200 ng/mL in subjects aged 20–25, falling to roughly 80 ng/mL by ages 60–70. This progressive decline has been associated with reduced plasma copper mobilization capacity and slower wound-repair kinetics in aged research subjects. The source of circulating GHK is thought to include collagen and proteoglycan degradation — as tissue collagen turnover slows with age, GHK generation from enzymatic degradation may fall in parallel. Longevity researchers studying GHK-Cu have focused on its downstream transcriptomic signature: Pickart and colleagues described a GHK-Cu-related gene expression pattern overlapping with genes upregulated in younger versus older tissue samples, though this work involves transcriptome correlation rather than direct mechanistic proof of causality. These findings motivate continued preclinical investigation into whether exogenous GHK-Cu can attenuate age-associated connective tissue decline in model organisms, with rodent skin and wound-closure assays as the primary research tools currently in use.

How should researchers distinguish and verify GHK-Cu versus free GHK when sourcing laboratory compounds?

Researchers should specify the exact molecular species in all procurement and experimental documentation. GHK-Cu is typically supplied as a blue lyophilized powder reflecting copper coordination, while free GHK is a white powder without copper loading. Mass spectrometry is the preferred verification method: free GHK (tripeptide free acid) has a calculated molecular weight of approximately 340 Da, while GHK-Cu as the copper(II) complex adds roughly 63.5 Da from one Cu²⁺ minus two protons from deprotonated coordination sites, yielding a characteristic adduct near 403 Da on positive-mode ESI-MS. Certificate of Analysis documentation from reputable research suppliers should include HPLC purity exceeding 95% by peak area alongside MS confirmation of the copper complex. Copper stoichiometry can also be independently verified by ICP-MS where precise copper-to-peptide ratios are needed. Because a subset of published studies uses "GHK-Cu" without rigorously confirming copper loading, some negative results in literature may reflect incorrect characterization of the sourced material. Specifying the precise species and analytical verification method in laboratory protocols prevents this source of experimental ambiguity.

GHK-Cu vs GHK: Copper Complex vs Free Tripeptide

Glycyl-L-histidyl-L-lysine is a naturally occurring tripeptide first isolated from human plasma in 1973. It circulates in the body at concentrations that decline significantly with age, and this decline has been linked in the literature to reduced wound repair capacity and changes in skin structural integrity. Researchers studying this compound encounter two overlapping names: GHK — the free tripeptide — and GHK-Cu — the copper(II)-bound complex. These are not interchangeable labels for the same entity. They describe chemically distinct species with meaningfully different receptor interactions, biological potency, and research applications.

This article examines the mechanistic and experimental differences between GHK and GHK-Cu, reviews the evidence base supporting each form, and compares their regulatory and compounding status as of 2026.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

GHK-Cu: mechanism and evidence base

GHK-Cu is the copper(II) chelate of the GHK tripeptide, in which the copper ion is coordinately bound through the imidazole nitrogen of histidine and the terminal amino group of glycine. The copper complex is the biologically active form identified in most published wound-healing and skin-biology research, and it is the species most commonly studied in cell culture and animal models.

Collagen and matrix remodeling. The most extensively documented activity of GHK-Cu in preclinical models is dual-directional regulation of the extracellular matrix. Studies published in FEBS Letters demonstrated that GHK-Cu stimulates synthesis of Type I, Type III, and Type IV collagen in human fibroblast cultures at concentrations of 10⁻⁸ to 10⁻⁹ mol/L — concentrations well within the physiological range. Simultaneously, GHK-Cu upregulates both matrix metalloproteinases (MMP-1, MMP-2) responsible for degrading damaged cross-linked matrix and their inhibitors (TIMP-1, TIMP-2). This balanced remodeling phenotype — synthesizing new matrix while clearing old — is mechanistically distinct from simple collagen stimulation and is proposed to account for the restored wound tensile strength observed in full-thickness animal wound models.

Copper transport and antioxidant function. The chelated copper(II) ion is released intracellularly in a controlled, bioavailable form. Free copper ions at equivalent concentrations are cytotoxic; the GHK peptide backbone moderates copper reactivity, enabling delivery of copper that contributes to superoxide dismutase (SOD) activity without triggering oxidative toxicity. This copper dismutase contribution is a mechanistic feature unique to GHK-Cu and absent from the copper-free tripeptide.

Gene expression modulation. Bioinformatic analyses by Pickart and Margolina (BioMed Research International, 2015; International Journal of Molecular Sciences, 2018) associated GHK-Cu with upregulation of genes governing wound repair, antioxidant defense (SOD2, catalase), and neurotrophic signaling, alongside downregulation of inflammatory and pro-senescent gene sets. These bioinformatic observations require controlled experimental validation but have positioned GHK-Cu in a broader research context. The orthopaedic narrative review indexed at PMID 41476424 characterizes GHK-Cu as showing "promise in wound healing and anti-inflammatory effects," while noting that no clinical data support musculoskeletal applications.

Angiogenesis and hair follicle biology. Preclinical models have documented GHK-Cu-stimulated upregulation of vascular endothelial growth factor (VEGF), enhanced endothelial cell migration, and increased hair follicle size and growth rate in animal studies. Anti-inflammatory cytokine reduction (TNF-α, IL-6) in macrophage culture models has also been reported in a dose-dependent pattern attributed to NF-κB pathway modulation.

GHK: mechanism and evidence base

GHK without copper coordination — the free tripeptide glycyl-L-histidyl-L-lysine — is itself biologically active, though with meaningfully different potency and mechanistic breadth compared to the copper complex.

Copper-binding affinity. The primary mechanistic role attributed to free GHK in vivo is serving as a copper carrier: the peptide has high affinity for Cu²⁺ ions and is proposed to act as a physiological copper delivery vehicle, with circulating GHK chelating copper before it exerts biological effects. Under this framework, the observed in vivo effects of GHK are largely mediated by GHK-Cu formed after copper coordination, and the free peptide functions as a transport precursor rather than an independent effector.

Gene expression effects. Research published in Molecules in 2015 (PMID 26527685, DOI 10.3390/molecules201219854) describes GHK as capable of modulating expression of more than 4,000 human genes in fibroblast cultures. Affected pathways include tissue remodeling, DNA repair, antioxidant response, and stem cell activity. This gene expression dataset is broad, but the extent to which effects observed in copper-replete culture media reflect free GHK activity versus GHK-Cu formed during incubation requires careful experimental interpretation.

Collagen and glycosaminoglycan synthesis. In the presence of copper, GHK stimulates collagen synthesis and glycosaminoglycan production consistent with GHK-Cu activity. In copper-depleted conditions, published data suggest substantially reduced potency, pointing toward the copper complex as the primary effector.

Wound healing models. Animal wound models using GHK show accelerated re-epithelialization and improved healing kinetics, though results tend to be somewhat less pronounced than equivalent studies using GHK-Cu, consistent with the copper-complex hypothesis of the active species.

Side-by-side comparison

Parameter	GHK-Cu	GHK (free tripeptide)
Molecular formula	C₁₄H₂₃CuN₆O₄⁺	C₁₄H₂₃N₆O₄⁺ (approx.)
Molecular weight	402.9 g/mol	~340 g/mol
Copper coordination	Yes — Cu(II) chelate	No (binds Cu²⁺ in solution)
Copper dismutase contribution	Yes	No (requires prior copper binding)
Primary research use	Wound healing, skin aging, hair follicle biology	Gene expression modulation; copper carrier studies
Potency in wound models	Higher (direct active species)	Lower unless copper-replete media
Regulatory status	Not approved; 503A Under Review	Not approved; no regulatory classification
WADA prohibited	No explicit listing	No explicit listing
Route in preclinical models	Topical, subcutaneous	Primarily in vitro, topical
Key citation	PMID 41476424	PMID 26527685

Differential research applications

The choice between GHK-Cu and GHK in published protocols reflects the mechanistic distinction above. GHK-Cu is the species selected when researchers require the copper-dependent biological effects — SOD-like antioxidant activity, confirmed collagen induction, or copper delivery to copper-depleted tissue environments. Dermatological studies examining wound tensile strength, skin aging biomarkers, or hair follicle biology have used GHK-Cu almost exclusively.

GHK (free tripeptide) appears in the literature primarily in gene expression studies where researchers want to distinguish copper-dependent from copper-independent peptide effects, or in protocols where the culture medium provides adequate copper for spontaneous GHK-Cu formation. The 2015 Molecules paper (PMID 26527685) is representative of this approach: broad transcriptomic analysis using GHK under standard culture conditions where trace copper would permit partial complexation.

From a research design perspective, studies using GHK in copper-replete environments may not be measuring free-peptide biology — they may be measuring GHK-Cu formed during the experiment. Researchers designing mechanistic assays who need to distinguish these should specify copper chelation controls. This interpretive ambiguity is a recognized methodological concern in the GHK literature.

When studying copper transport biology specifically, free GHK is the appropriate research tool because the question is how the peptide binds and delivers copper, which requires the uncomplexed form.

Regulatory and compounding status

Neither GHK-Cu nor free GHK holds FDA approval for any clinical indication. GHK-Cu appears in 503A compounding discussions and is currently listed as "Under Review" in the context of bulk drug substance nominations submitted to the FDA's 503A bulk drug substance list. The outcome of that review process will determine whether licensed 503A compounding pharmacies may continue to use GHK-Cu as a bulk ingredient.

Free GHK (uncomplexed tripeptide) has not been the subject of specific FDA 503A or 503B nominations reviewed in publicly available records as of early 2026. It does not carry a specific compounding designation.

Neither compound is listed on the WADA 2026 Prohibited List. Researchers at institutions subject to anti-doping policy should independently verify current WADA status for their specific protocol context, as prohibited list categories can cover classes of compounds beyond explicitly named substances.

No EMA approval exists for either compound. Research-grade use is governed by institutional biosafety and research ethics frameworks rather than regulatory approval.

Cited studies

PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." (Journal of the American Academy of Orthopaedic Surgeons, 2026). Reviews GHK-Cu evidence in musculoskeletal research context. https://doi.org/10.1155/2015/648108
PMID 26527685 — "Glycyl-L-histidyl-L-lysine (GHK) tripeptide and its role in tissue repair and gene modulation." (Molecules, 2015). Primary characterization of free GHK gene expression activity across >4,000 human genes. https://doi.org/10.3390/molecules201219854

For the full compound profiles of each peptide, see the library entries at /library/ghk-cu/ and /library/ghk/.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.